AI Articles and Analysis about Research and development

This article/interview analysis is sponsored by BenevolentAI and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Dozens of GPT-driven products are already on the market, and hundreds more are in development. These tools collectively aim to revolutionize traditional roles and processes, transforming them into dynamic, parallelized workflows using variants of LLM models, such as AutoGPT. Tools like GitHub Copilot, powered by OpenAI's Codex, are demonstrating significant improvements in developer productivity, with some studies showing up to a 55% increase in task completion speed. 

This interview analysis is sponsored by Pieces and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

According to research from the American Society for Biochemistry and Molecular Biology, nine out of 10 drugs fail to make it to market in the clinical trials process. Researchers in the cited studies found that 40-50% of these failures are due to a lack of clinical efficacy, meaning that the drug is not able to produce its intended effect in people, and 30% were due to unmanageable toxicity or side effects.

Far beyond surface-level 'chatbot' software, and other customer-facing support systems, the same generative AI (GenAI) capabilities having direct impacts across language workflows in front-office tasks in financial and legal services is also having a direct impact on how research teams in the life sciences space are targeting solutions for rare diseases and novel treatments. 

Sanofi is a global healthcare and pharmaceutical company. Founded in 1973, it aims to unlock and maximize the potential of critical medicines, vaccines, and self-care solutions for individuals. It accomplishes this across four global business units: Specialty Care, Vaccines, General Medicines, and Consumer Healthcare. 

This interview analysis is sponsored by Deloitte and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

This interview analysis is sponsored by Riskified and was written, edited and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.